摘要
目的观察临床应用丁苯酞软胶囊改善帕金森痴呆患者认知功能和日常生活能力的效果及其对相关因子的影响。方法采用前瞻性研究方法,将2012年8月至2016年8月邯郸市第一医院收治的帕金森痴呆患者92例按照随机平行分组法随机分为对照组和观察组,每组各46例。对照组患者给予临床常规治疗,观察组则在常规治疗基础上联合应用丁苯酞软胶囊治疗,对比分析两组患者的临床疗效,蒙特利尔认知评估量表(MoCA)、日常生活能力量表(ADL)评分,C反应蛋白(CRP)、帕金森病蛋白7(PARK7)及神经营养因子-3(NT-3)水平。结果患者治疗后临床治疗总有效率组间比较,观察组明显高于对照组(91. 3%vs. 76. 1%,P <0. 05);两组患者治疗前MoCA、ADL评分组间比较,差异均无统计学意义(21. 15±3. 14 vs. 21. 22±3. 47,54. 62±2. 13 vs. 54. 63±3. 39,P> 0. 05);两组患者治疗后MoCA、ADL评分均较治疗前明显升高,差异具有统计学意义(P <0. 05),且观察组治疗后MoCA、ADL评分明显高于对照组(P <0. 05);两组患者治疗前CRP、PARK7、NT-3水平组间比较,差异均无统计学意义(P> 0. 05);两组患者治疗后CRP、PARK7均较治疗前明显下降,NT-3水平明显升高(P <0. 05),观察组CRP、PARK7、NT-3变化幅度明显高于对照组,差异具有统计学意义(P <0. 05)。结论丁苯酞软胶囊治疗帕金森痴呆可明显提高患者认知功能和日常生活能力,改善相关因子水平,可在临床推广应用。
Objective To observe the clinical application of Butylphthalide soft capsules improve cognitive function in patients with Parkinson＇s disease dementia and daily life ability effect and its influence on related factors. Methods By prospective study, 92 Parkinson patients with dementia in the first hospital of Handan from August 2012 to August 2016 were randondy divided into the control group and the observation group according to the random parallel grouping method, with 46 cases in each group. The patients in the control group were treated with routine clinical treatment, and the observation group was combined with Butylphthalide Soft Capsules therapy on the basis of routine treatment. The clinical efficacy of the two groups was compared and analyzed in the two groups. The Montreal cognitive assessment scale （MoCA） , the daily living ability scale （ADL） score, the C reaction egg white （CRP） , Parkinson＇s disease protein 7 （PARK7） and the level of neurotrophic factor - 3 （NT - 3） were compared. Results Compared with the control group （91.3% vs. 76.1% , P 〈 0.05） , the observation group was significantly higher than the control group （91.3 % vs. 76.1% , P 〈 0.05 ） , and there was no significant difference between the two groups before treatment （21.15 ±3.14 vs. 21.22±3.47, 54.62±2.13 vs. 54.63 ±3.39, P 〉0.05）. The two groups were treated with MoCA and ADL scores after treatment. The difference was statistically significant compared with that before treatment （ P 〈 0.05 ）. There was no significant difference between the two groups of CRP, PARK7 and NT - 3 before treatment （ P 〉 0.05 ）. The CRP and PARK7 in the two groups were significantly lower than before the treatment, and the NT - 3 level increased significantly （ P 〈 0.05） , and the observation group was CRP, PARK7, NT -. 3 the amplitude of change was significantly higher than that of the control group, and the difference was statistically significant （ P 〈 0.05）. Conclusion The treatment of Parkinson＇s dementia with clinical application of buphthalein soft capsule can significantly improve the cognitive function and daily life ability of patients, and improve the correlation factor level, which can be applied in clinical application.
作者
宋丽倩
李晓利
王晓静
武一平
林杰
智孔亮
SONG Li-qian;LI Xiao-li;WANG Xiao-jing(Department of Neurology,Handan City First Hospital,Handan Hebei 056000,China)
出处
《临床和实验医学杂志》
2018年第22期2416-2419,共4页
Journal of Clinical and Experimental Medicine
基金
河北省医学科学研究重点课题资助项目(编号:20171089)
关键词
帕金森痴呆
丁苯酞软胶囊
认知功能
日常生活能力
Parkinson dementia
Butylphthalein soft capsule
Cognitive function
Daily life ability
